IBRUNITIME 25 (Iguratimod 25 mg) – Steris Healthcare

What is IBRUNITIME 25 (Iguratimod 25 mg) For?

IBRUNITIME 25 is built around Iguratimod 25 mg, a small-molecule DMARD increasingly used in rheumatology practice for the management of moderate to severe rheumatoid arthritis (RA). Unlike conventional NSAIDs that only mask pain, Iguratimod works at the immunological level, reducing the inflammatory cascade responsible for joint swelling, stiffness, and progressive cartilage damage. It is often prescribed either as monotherapy or in combination with other DMARDs such as methotrexate, particularly in patients who show an inadequate response to first-line therapy. Manufactured under WHO-GMP and ISO 9001:2018 certified conditions by Steris Healthcare, IBRUNITIME 25 delivers dependable potency and consistent therapeutic quality batch after batch.

Why It's Important

Rheumatoid arthritis is a chronic autoimmune condition that, if inadequately controlled, can lead to irreversible joint deformity, disability, and reduced quality of life. Early and effective DMARD therapy is critical to slowing disease progression and preserving joint function. IBRUNITIME 25 fills an important niche for patients who need an additional or alternative treatment option beyond conventional DMARDs, especially where tolerability or response has been a concern. Its distinct mechanism makes it a valuable addition to combination regimens in modern rheumatology protocols.

Key Benefits of IBRUNITIME 25 (Iguratimod 25 mg)

What Are the Benefits?

  • Helps reduce joint inflammation, swelling, and stiffness associated with RA
  • Slows structural joint damage when used consistently as prescribed
  • Effective as an add-on therapy alongside methotrexate in inadequate responders
  • Oral tablet formulation offers convenient dosing compared to injectable biologics
  • Supports improved physical function and reduced disease activity scores over time
  • Manufactured with strict quality control by Steris Healthcare for reliable efficacy

Mechanism of Action

Iguratimod works through a multi-pathway immunomodulatory mechanism. It suppresses the production of pro-inflammatory cytokines such as IL-6, IL-1β, and TNF-α by inhibiting NF-κB activation in immune cells. It also modulates B-cell activity, reducing immunoglobulin production, which is particularly relevant in autoimmune-driven joint inflammation. Additionally, Iguratimod has been shown to inhibit osteoclast-mediated bone resorption, offering a degree of protection against the bone erosion commonly seen in progressive rheumatoid arthritis. This combined anti-inflammatory and bone-protective action distinguishes it from many conventional DMARDs.

Side Effects

Most patients tolerate IBRUNITIME 25 reasonably well, though some may experience:

  • Nausea or mild gastrointestinal discomfort
  • Elevated liver enzymes
  • Mild diarrhea
  • Headache
  • Menstrual irregularities in some female patients

Serious Side Effects Of IBRUNITIME 25

Seek immediate medical attention if you notice:

  • Signs of liver dysfunction (yellowing of skin/eyes, dark urine)
  • Severe or persistent gastrointestinal bleeding
  • Unusual bruising or bleeding (low platelet count)
  • Signs of infection (fever, chills) due to immune suppression
  • Severe allergic reaction (rash, swelling, difficulty breathing)

Available Substitute For IBRUNITIME 25

Patients unable to access IBRUNITIME 25 may be prescribed alternative Iguratimod 25 mg brands available in India, based on their treating rheumatologist's advice, since bioavailability and excipient quality can differ between manufacturers. Any brand substitution should be made only under medical supervision, with regular liver function and blood count monitoring maintained regardless of the brand used.

Dosage Guidelines For IBRUNITIME 25

PopulationRecommended DoseFrequency
Adults (initial)25 mgOnce daily
Adults (maintenance)25 mgTwice daily (as advised)
Elderly/Hepatic-impairedAs advised by physicianIndividualised

Tablets should be taken with water, at consistent times each day, strictly as directed by a registered medical practitioner. Regular liver function tests and blood counts are recommended during therapy.

Precautions & Warnings

  • Avoid use in patients with known hypersensitivity to Iguratimod
  • Contraindicated in patients with severe hepatic or renal impairment
  • Regular monitoring of liver enzymes and complete blood counts is essential during treatment
  • Use with caution in patients on concurrent warfarin therapy due to potential interaction
  • Not recommended during pregnancy or breastfeeding
  • Increased susceptibility to infections; avoid use during active infections
  • Keep out of reach of children

Conclusion

IBRUNITIME 25 (Iguratimod 25 mg) from Steris Healthcare provides an effective, oral DMARD option for patients managing rheumatoid arthritis, particularly where combination therapy is needed. With its dual anti-inflammatory and bone-protective mechanism, backed by WHO-GMP manufacturing standards, IBRUNITIME 25 stands as a dependable choice for rheumatologists and patients seeking better long-term disease control.

Comments

Post a Comment

Popular posts from this blog

Steris Healthcare: Committed to Quality Healthcare and Pharmaceutical Excellence

 Healthcare is one of the most significant sectors influencing the well-being of individuals and communities. As medical science advances, the demand for reliable pharmaceutical products continues to grow. Patients, healthcare professionals, and medical institutions all depend on high-quality medicines that meet strict standards of safety and effectiveness. Pharmaceutical companies play a vital role in ensuring these products are developed, manufactured, and delivered responsibly. Steris Healthcare is committed to supporting better healthcare by providing quality pharmaceutical products designed to improve patient outcomes. Guided by innovation, integrity, and continuous improvement, the company strives to meet the evolving needs of the healthcare industry while maintaining high standards of quality and customer satisfaction. A Vision for Better Healthcare Every successful healthcare organization begins with a clear vision. Steris Healthcare believes that quality medicines and de...
Read more

N-Acetyl L-Cysteine (NAC), Pine Bark Extract and Resveratrol Tablets for Daily Wellness

Image
  N-Acetyl L-Cysteine (NAC), Pine Bark Extract & Resveratrol Tablets: Ingredients and Health Benefits Today’s lifestyle in India has changed a lot. Long working hours, stress, pollution, processed food, and lack of physical activity are affecting overall health. Many people feel tired, low on energy, or struggle with metabolic and hormonal balance tablet . One of the main reasons behind this is oxidative stress. Oxidative stress happens when harmful molecules called free radicals damage the body’s cells. Over time, this may affect immunity, liver health, heart health, skin, and overall wellness.  STYLECYSTIN ENDO is a specially designed antioxidant tablet that contains N-Acetyl L-Cysteine (NAC), Pine Bark Extract, and Resveratrol . This powerful combination supports cellular protection, improves antioxidant levels, and promotes better internal balance. It is commonly recommended as supportive therapy in metabolic conditions, women’s health concerns, and lifestyle-related ...
Read more
Megestrol Acetate 160 mg: MAGRAL 160 Uses, Benefits & Safety MAGRAL 160 contains Megestrol Acetate 160 mg and is marketed by Steris Healthcare . Megestrol acetate is a synthetic progestin that is used in specific clinical situations, particularly for managing anorexia, cachexia, or significant unexplained weight loss associated with advanced cancer or AIDS , depending on the approved indication and medical judgment. It is a prescription medicine and should be used under the supervision of a qualified healthcare professional. Megestrol acetate is not a general-purpose appetite booster or routine weight-gain medicine. Before treatment, the underlying reason for poor appetite or weight loss should be evaluated. What is MAGRAL 160 For? MAGRAL 160 may be prescribed when significant appetite loss or involuntary weight loss occurs in certain serious medical conditions. Megestrol acetate can help increase appetite and may contribute to weight gain in appropriately selected patients. Th...
Read more